Acute kidney injury as the most important predictor of poor prognosis after interventional treatment for aortic stenosis.


Journal

Kardiologia polska
ISSN: 1897-4279
Titre abrégé: Kardiol Pol
Pays: Poland
ID NLM: 0376352

Informations de publication

Date de publication:
2022
Historique:
received: 03 08 2022
accepted: 03 08 2022
pubmed: 5 8 2022
medline: 16 11 2022
entrez: 4 8 2022
Statut: ppublish

Résumé

Aortic stenosis (AS) is the most common acquired valvular disease. There are two methods of interventional treatment: surgical aortic valve replacement (SAVR) and transcatheter aortic valve implantation (TAVI). The choice between SAVR and TAVI depends on the assessment of individual perioperative risk and long-term treatment outcomes. It is essential to identify factors that may influence the outcomes of the treatment to minimize their negative effects. The study aimed to identify the most important risk factor which affects treatment outcomes in patients with AS undergoing SAVR/TAVI. This study reviewed retrospectively patients with AS who underwent SAVR or TAVI. The primary outcomes included incidences of major adverse cardiovascular events (MACE) defined as cardiovascular death, stroke, and hospitalization for cardiovascular issues assessed over a one-year follow-up period. An occurrence of postprocedural AKI (acute kidney injury) was identified as an independent predictor of MACE. The study included 78 patients, with the same number of subjects in each group (SAVR/TAVI [n = 39]). Twenty-nine patients developed AKI. It was similar in both groups (SAVR [n = 15]; TAVR [n = 14]). In the SAVR group, 13 (33%) patients developed at least one MACE compared to 5 (13%) patients in the TAVI group. AKI and the type of procedure (SAVR) were shown to be significantly and independently associated with the development of MACE (P = 0.01 and P = 0.03, respectively) as shown in the Cox multivariable regression model. Our study demonstrated that AKI is the strongest predictor of major adverse cardiovascular events after using both methods of aortic valve replacement (SAVR/TAVI).

Sections du résumé

BACKGROUND
Aortic stenosis (AS) is the most common acquired valvular disease. There are two methods of interventional treatment: surgical aortic valve replacement (SAVR) and transcatheter aortic valve implantation (TAVI). The choice between SAVR and TAVI depends on the assessment of individual perioperative risk and long-term treatment outcomes. It is essential to identify factors that may influence the outcomes of the treatment to minimize their negative effects.
AIMS
The study aimed to identify the most important risk factor which affects treatment outcomes in patients with AS undergoing SAVR/TAVI.
METHODS
This study reviewed retrospectively patients with AS who underwent SAVR or TAVI. The primary outcomes included incidences of major adverse cardiovascular events (MACE) defined as cardiovascular death, stroke, and hospitalization for cardiovascular issues assessed over a one-year follow-up period. An occurrence of postprocedural AKI (acute kidney injury) was identified as an independent predictor of MACE.
RESULTS
The study included 78 patients, with the same number of subjects in each group (SAVR/TAVI [n = 39]). Twenty-nine patients developed AKI. It was similar in both groups (SAVR [n = 15]; TAVR [n = 14]). In the SAVR group, 13 (33%) patients developed at least one MACE compared to 5 (13%) patients in the TAVI group. AKI and the type of procedure (SAVR) were shown to be significantly and independently associated with the development of MACE (P = 0.01 and P = 0.03, respectively) as shown in the Cox multivariable regression model.
CONCLUSIONS
Our study demonstrated that AKI is the strongest predictor of major adverse cardiovascular events after using both methods of aortic valve replacement (SAVR/TAVI).

Identifiants

pubmed: 35924995
pii: VM/OJS/J/91252
doi: 10.33963/KP.a2022.0182
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1032-1038

Auteurs

Anita Korczak (A)

2nd Department of Cardiology, Medical University of Lodz, Department of Cardiology and Cardiac Surgery of the Hospital of the Clinical and Didactic Centre in Lodz, Łódź, Poland. anita.korczak@umed.lodz.pl.

Robert Morawiec (R)

2nd Department of Cardiology, Medical University of Lodz, Department of Cardiology and Cardiac Surgery of the Hospital of the Clinical and Didactic Centre in Lodz, Łódź, Poland.

Michał Stegienta (M)

2nd Department of Cardiology, Medical University of Lodz, Department of Cardiology and Cardiac Surgery of the Hospital of the Clinical and Didactic Centre in Lodz, Łódź, Poland.

Aleksandra Ryk (A)

Department of Biostatistics and Translational Medicine, Medical University of Lodz, Łódź, Poland.

Andrzej Walczak (A)

Department of Cardiac Surgery of the Hospital of the Clinical and Didactic Center in Lodz, Medical University of Lodz, Łódź, Poland.

Jan Krekora (J)

2nd Department of Cardiology, Medical University of Lodz, Department of Cardiology and Cardiac Surgery of the Hospital of the Clinical and Didactic Centre in Lodz, Łódź, Poland.

Michał Krejca (M)

Department of Cardiac Surgery of the Hospital of the Clinical and Didactic Center in Lodz, Medical University of Lodz, Łódź, Poland.

Jarosław Drożdż (J)

2nd Department of Cardiology, Medical University of Lodz, Department of Cardiology and Cardiac Surgery of the Hospital of the Clinical and Didactic Centre in Lodz, Łódź, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH